Skip to main content
. Author manuscript; available in PMC: 2018 Feb 15.
Published in final edited form as: Cancer. 2016 Aug 15;122(22):3456–3463. doi: 10.1002/cncr.30270

Figure 2.

Figure 2

(A) Kaplan-Meier plot of progression-free survival in patients who were initiated on standard-dose erlotinib versus patients initiated on reduced-dose erlotinib. (B) PFS in patients who were initiated and maintained on standard-dose erlotinib, patients who were initiated and maintained on reduced-dose erlotinib, and patients who were initiated on standard-dose erlotinib but on a reduced dose by the four month landmark. (C) OS in patients who were initiated on the reduced dose versus the MTD of erlotinib.